==== Front Ann Saudi MedAnn Saudi MedAnnals of Saudi Medicine0256-49470975-4466King Faisal Specialist Hospital and Research Centre 2379342610.5144/0256-4947.2013.247asm-3-247Original ArticleMortality among tuberculosis patients in Saudi Arabia (2001–2010) Abouzeid Mohammad S. abAl Hakeem Rafaat F. bMemish Ziad A. b a Public Health and Community Medicine, Tanta University, Egypt b Public Health Directorate – Communicable Diseases, Ministry of Health, Riyadh, Saudi ArabiaCorrespondence: Ziad A. Memish, MD, FACP, FRCP (C), FRCP (Edin), FRCP (Lon), Deputy Minister of Health for Public Health, Ministry of Health, Riyadh 11176, Saudi Arabia, T: 966-1-2124052, F: 966-1-2125052, zmemish@yahoo.comMay-Jun 2013 33 3 247 252 Copyright © 2013, Annals of Saudi Medicine2013This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.BACKGROUND AND OBJECTIVES Tuberculosis (TB) still contributes to deaths in Saudi Arabia, among both Saudis and non-Saudis. Exploring the trend of deaths caused by TB and determinants associated with high fatality rate among TB patients is considered as a part of monitoring and evaluation of the performance of National Tuberculosis Control Program to help planners improve policies and procedures used to achieve the targets of TB control. DESIGN AND SETTINGS The current study is a retrospective one, which used the official notifications of NTP in Saudi Arabia over a period of 10 years (2001–2010). METHODS A 10-year retrospective study included all TB cases registered in Saudi Arabia with known outcome of survival or death while under anti-TB therapy covering the period January 1, 2001, to December 31, 2010. RESULTS Mortality among TB patients show a declining trend among Saudis starting from the year 2003 (7.2%–6.1%) and a stagnant trend among non-Saudis. Saudi nationality was associated with higher fatality rate compared to non-Saudis (6.4% and 5.4%, respectively). Mortality was positively correlated with advancing age, male sex among Saudis (7.3% compared to 5.3% among females), and female sex among non-Saudis (6% compared to 5% among males), prior history of anti-TB therapy, smear positivity, and human immunodeficiency virus (HIV) seropositivity. CONCLUSIONS We recommend WHO to modify the definition of death among TB patients. We recommend NTP in Saudi Arabia to adopt and implement International Classification of Diseases (ICD10) for TB patients’ registration, improve health care services provided for elderly, monitor and strengthen NTP performance to decrease defaulter and early detect and treat patients, initiate a collaborative TB/HIV activities, and screen all suspected TB patients for HIV. In addition to these, more extended research has to be initiated concerning delayed diagnosis and comorbidities with TB. ==== Body Despite big investments in the field of tuberculosis (TB) control since the declaration of TB as a global health problem in 1993,1 TB remains one of the greatest public health challenges worldwide. In the year 2010, there were 8.8 million (range, 8.5–9.2 million) incident cases of TB, 1.1 million (range, 0.9–1.2 million) deaths from TB among human immunodeficiency virus (HIV)-negative people, and an additional 0.35 million (range, 0.32–0.39 million) deaths from HIV-associated TB.2 TB is a disease of poverty. In many parts of the globe, the resources are deficient and health systems are overwhelmed, which lead to the sloppy implementation of directly observed treatment (DOTS) programs and exacerbation of the TB problem.3 DOTS is the only available method for reducing TB transmission and deaths worldwide and preventing emergence of multidrug resistant strains.4 The implementation of DOTS in Yavatmal, India, resulted in doubling of the success rate and reduction in the death rate with an approximate 18 additional lives saved per 100 patients treated.5 According to the WHO definition, any case died while under anti-TB treatment is considered regardless of the cause of death.6 Many risk factors have been claimed as determinants of death among TB patients such as old age, prior history of TB, multidrug resistance, 7 HIV co-infection,8 and non-compliance with treatment,9 in addition to delayed therapy.4 Although Saudi Arabia has adopted the global strategy for TB control and has implemented directly the observed treatment, i.e., the short course since the year 2000, TB still represents an important public health problem in the country, affecting all age groups and Saudis and non-Saudis alike. As most of non-Saudis are originated from high TB endemic areas of the world, they had nearly twice the TB incidence rate compared to Saudis.10 In the current article, the official national surveillance data of National Tuberculosis Control Program (NTP) regarding mortality over a period of 10 years was analyzed to determine the mortality trends and explore some determinants associated with deaths among TB patients. METHODS A retrospective 10-year study included all TB cases reported in Saudi Arabia during the period January 1, 2001, to December 31, 2010. Saudi Arabia had mandatory reporting of all TB cases, and returns were made monthly and notified by the patient’s name to the central unit of the program and then entered into an Epi-info program. Patients were classified according to WHO criteria11 and treated according to the adopted WHO protocols.12 New patients were treated by 4 drugs for 2 months (intensive phase) followed by 2 drugs for 4 months (continuation phase). New patients who remained smear positive by the end of the second month of treatment had their intensive phase and continuation phase extended for an extra month. Retreatment patients were treated by 5 drugs for 3 months (streptomycin always discontinued after 2 months) followed by 3 drugs for 5 months. All patients under treatment were followed up by the treating physicians and by district coordinator till the end of treatment or death to confirm the outcome of the treatment. District coordinators in all districts (20 districts) were mandated to notify the results of treatment outcomes for all registered prenotified patients on a monthly basis to the central unit of National Tuberculosis Control Programme, where the data entered into an electronic file, which then joined to one of the prenotified patients using the district name and the unique TB code. Only patients with confirmed death were included. Patients who left the country before completing their treatment period and those who were excluded from the registers because of misdiagnosis in addition to those without confirmed treatment outcomes were excluded. Patients who died while under anti-TB treatment were considered in analysis, regardless of the primary cause of death. In calculation of the case fatality rate, the numerator used was the number of patients died while under anti-TB therapy, regardless of the cause, and the denominator was the total patients registered for anti-TB therapy and had a confirmed notification of outcome. Data were then organized, tabulated, and analyzed for case fatality rates (calculated as percentage) by year, nationality, sex, case type, form of TB, HIV status, and age using SPSS statistical package, version 16. Chi-square was used for linear trends; Pearson chi-square technique and Poisson log linear regression were used as appropriate. The significance level was set at .05. Ethics Statement Ethical approval or written patient consent were not required for the study, as this was a retrospective review of routine surveillance data collected anonymously by the Saudi Arabia NTP and also because Saudi Arabia Ministry of Health had a mandate to review and evaluate the NTP performance. RESULTS The case fatality rate shows an upward trend starting from the year 2001 reaching a peak in the year 2003 (7.2% and 6.2% among both Saudis and non-Saudis, respectively). Starting from the year 2004, the result shows a declining trend to exhibit a total decline of 20.4% among Saudis and 27.3% among non-Saudis, among both Saudi and non-Saudis. Changes in the mortality rate reported among Saudis were statistically significant (P<.05) but that among non-Saudis were not significant (P>.05), (Table 1). The case fatality rate was found to be increased with the increase in age, among both Saudis and non-Saudis. The highest rates reported among those aged ≥65 years (20.8% among Saudis and 25.2% among non-Saudis). The rate among Saudis increased from 1.2% among those aged ≤15 years to 20.1% among those aged ≥65 years. While among non-Saudis the rate increased from 3.1% among those aged ≤15 years to 25.2% among those aged ≥65 years. The total case fatality rate was significantly higher among Saudis (6.4%) compared to non-Saudis (5.4%) (OR=1.2, 95% CI 1.1–1.33), (Table 2). Elderly people (≥65 years) represent 46.3% of the total deaths among Saudis compared to only 13.5% among non-Saudis. The productive age groups (15–44 years) still represent the greatest proportion of TB mortality among both Saudis and non-Saudis (36.8% and 71.8%, respectively). Concerning sex, the case fatality rate was significantly higher among Saudi males (7.3%) compared to Saudi females (5.3%) (OR=1.4, 95% CI=1.24–1.58). However, non-Saudi females were more vulnerable to death (6%) than non-Saudi males (5%) (OR=1.22, 95% CI=1.24–1.58). Retreatment TB patients were significantly more vulnerable to death than new TB patients, among both Saudis and non-Saudis. As regards to the form of TB, the pulmonary smear positive form was found to be more associated to death among both Saudis and non-Saudis (95% CI 1.21–1.53 and 1.24–1.71, respectively). Among TB patients with known HIV status, HIV seropositive patients were significantly more prone to death than HIV seronegative patients, among both Saudis and non-Saudis (95% CI=2.7–10.06 and 6.98–21.22, respectively], (Table 3). Mortality data were analyzed by province, but there were no statistical significant differences, and all provinces showed figures around the national case fatality rate. DISCUSSION According to the WHO and Stop TB Partnership, the targets are to halve the prevalence and death rates by 2015 compared with their levels in 1990 and to reduce the global incidence of active TB to 1 case per 1 million population by the year 2050.13 Saudi Arabia has achieved the target related to the death rate from TB compared to 1990 (12% in 1990)14 and case fatality rate showed a declining trend since the year 2003, that could be attributed to the widespread network of health care facilities providing services free of charge for all TB patients. Case fatality rate from TB in the country is also, lower than that reported in other countries of the region, except for Iran and United Arab Emirates.2 Actually, WHO should modify the definition of death from TB to include only patients where TB was the primary cause of death according to the International Classification of Diseases (ICD10).15 Strengthening the laboratory network and provision of recent molecular technology could result in more decline in fatality from TB as a result of early diagnosis and treatment of suspected patients. Age is an important determinant of death from TB. The case fatality rate was found to be positively correlated with age, among both Saudis and non-Saudis. Patients with age group ≥65 years showed the highest case fatality rate followed by those in the age group 55 to 64 years, and this agrees with the findings of Ochoa et al. in Cuba.16 The high case fatality rate among this age group was coincident with the high incidence rate of TB among this age group (65.2/100 000 in the year 2000).10 This could be attributed to other comorbidities prevailed among elderly people such as cardiovascular diseases, cancer,7 liver disease, renal diseases, and diabetes,17,18 which may be the primary cause of death rather than TB. Also these comorbidities may change the presentation of TB making it difficult to diagnose and treat, in addition to the increased risk of anti-TB drugs toxicity.19 Moreover, elderly people are exposed to unfavorable living conditions, malnutrition, and less access to health care. Elderly TB patients may also present with atypical nonspecific symptoms that may delay diagnosis and treatment and add to the risk of death.20 Mortality still mostly affects the productive age groups, which means that actions have to be taken to save the work force in the country and worldwide. Elderly patients (≥65 years) represent a respective proportion of deaths among Saudis compared to non-Saudis. This reflects only the demographic composition of both communities rather than indicating old age as a determinant for death among Saudis. The male sex by itself could not be considered as a risk factor for death in TB patients, as there is other confounding. Being more prone to death has been attributed to low compliance with treatment leading to repeated short interruptions or defaulting from treatment21 and also the effect of social stigma that affects female access to health care leading to delayed diagnosis and treatment.10 Saudi males are more prone to death from TB than females, and this agrees with other studies.7,16, 22 In 2008, the analysis of European surveillance data showed that male TB patients had approximately 50% higher risk of death.23 In contrast, non-Saudi females were found to be more prone to death, a finding that could be linked to the higher incidence of TB among non-Saudi females who were mostly of low socioeconomic status and originated from countries of high burden of TB.10 Regarding the case type, the history of prior TB was associated with an increased risk of death among both Saudis and non-Saudis. The result was in agreement with the findings of Shen et al in China 2009,24 who reported that retreatment patients were 50% more prone to death than new cases. This could not be attributed to the previous history of TB but to behavioral causes such as noncompliance with treatment or defaulting that led to the failure of treatment when they were new cases, and which could also be a cause of the second failure of treatment and occurrence of complication and finally death. Sputum smear positivity was found to be associated with high fatality among both Saudis and non-Saudis, which was in agreement with the findings of Shen et al24 in China. They attributed these findings to high bacillary load, severe form of TB, and difficulty with treatment. In contrast Davis et al in England25 reported that pulmonary smear negative TB was more associated with mortality, a finding that could be attributed to delayed diagnosis and therapy till it presents with a severe form. HIV is a known risk factor for TB infection and mortality26 because it is associated with atypical presentation leading to diagnostic delay and therapy contributing to mortality, especially in the case of advanced immune suppression.27 Saudi Arabia is not affected by the pandemic of HIV,28 even for non-Saudis who are mandated to check their HIV status at their home countries before having entry visa and on their arrival to the country before issuing the official residential permission (Iqama). In the current study, HIV seropositive patients, among both Saudis and non-Saudis were more prone to death, which was in agreement with other studies.27,29 As the proportion of TB patients with the known HIV status in the country is very low, improving the management of TB suspects by including HIV screening, monitoring the collaboration between NTP and HIV/AIDS program in the country to screen all registered TB patients for HIV, and initiatiating antiretroviral therapy for those living with HIV will improve this proportion. In conclusion, the current study revealed that the mortality rate from TB showed a declining trend among Saudis and stagnant trend among non-Saudis. The Saudi nationality was associated with the higher fatality rate, which reflected the demographic composition of the Saudi population where elderly proportion was higher than that among non-Saudis. Mortality was positively correlated with advancing age, male sex among Saudis and female sex among non-Saudis, prior history of anti-TB therapy, smear positivity, and HIV seropositivity. We recommend WHO to modify the definition of death among TB patients to include only deaths where TB is the primary cause. We recommend NTP in Saudi Arabia to adopt and implement ICD10 for the registration of TB patient, improve health care services provided for elderly, monitor and strengthen NTP performance to decrease defaulter and early detect and treat patients, initiate a collaborative TB/HIV activities and screening all suspected TB patients for HIV. In addition, more extended research has to be initiated concerning delayed diagnosis and comorbidities with TB. Table 1 Registered TB cases and deaths in Saudi Arabia (2001–2101) by year and nationality. Year Saudi Non-Saudi Registered Died Fatality rate (%) Registered Died Fatality rate (%) 2001 1833 108 5.3 1075 45 4.2 2002 1840 118 5.8 1164 56 4.8 2003 1833 143 7.2 1115 69 6.2 2004 1839 137 6.7 1174 66 5.6 2005 2003 143 6.7 1285 77 6.0 2006 2115 129 5.8 1345 71 5.3 2007 2179 137 5.7 1506 73 4.9 2008 2228 152 5.9 1490 67 4.5 2009 2237 118 5.6 1436 87 6.1 2010 2321 127 5.7 1650 100 6.1 Total 20428 1312 6.4 13240 711 5.4 χ2a 5.2 1.5 P <.05 >.05 TB: Tuberculosis. a Chi-square test for linear trend. Note: Saudis vs. non-Saudis; OR=1.2195% CI (1.1–1.33). Table 2 Registered TB cases and deaths in Saudi Arabia (2001–2010) by nationality and age group. Nationality Age group Total Died Fatality rate (%) 95% CIa Lower Higher Saudi 0–14 1330 16 1.2 −3.274 −2.296 15–24 4796 87 1.8 −2.623 −2.175 25–34 4235 127 3.0 −2.089 −1.707 35–44 2652 119 4.5 −1.691 −1.299 45–54 2358 150 6.4 −1.325 −0.969 55–64 2029 205 10.1 −0.843 0.527 65+ 3028 608 20.1 0 Total 20428 1312 6.4 Non-Saudi 0–14 615 19 3.1 −2.565 −1.591 15–24 2884 74 2.6 −2.585 −1.981 25–34 4470 170 3.8 −2.143 −1.643 35–44 2579 152 5.9 −1.710 −1.200 45–54 1602 115 7.2 −1.527 −0.986 55–64 709 85 11.9 −1.033 −0.451 65+ 381 96 25.2 0 Total 13240 711 5.4 TB: Tuberculosis. a Poison Log linear analysis. Table 3 Registered TB cases and deaths in Saudi Arabia (2001–2010) by sex, cases type, form of TB, and HIV status. Characteristics Registered Died Fatality rate (%) OR 95% CI Sex Saudi F 8675 459 5.3 1.4 1.2–1.58 M 11752 853 7.3 Non-Saudi F 5254 314 6.0 1.22 1.04–1.42 M 7986 397 5.0 Case Type Saudi New 19267 1211 6.3 1.42 1.14–1.77 Retreatment 1161 101 8.7 Non-Saudi New 12610 673 5.3 1.14 0.8–1.6 Retreatment 630 38 6.0 Form of TB Saudi SS+a 9321 688 7.4 1.34 1.20–1.50 Other formsb 11107 624 5.6 Non-Saudi SS+a 6286 437 7.0 1.26–1.72 Other formsb 6954 274 4.0 1.47 HIV Status Saudi Seronegative 2624 128 4.9 5.25 2.7–10.06 Seropositive 66 14 21.2 Non-Saudi Seronegative 2028 104 5.1 12.18 6.98–21.22 Seropositive 68 27 39.7 TB: Tuberculosis, HIV: human immunodeficiency virus. a Pulmonary smear positive TB. b Includes pulmonary smear negative and extra-pulmonary forms. ==== Refs REFERENCES 1 World Health Organization Report on the technical consultation meeting on Tuberculosis in the Eastern Mediterranean Region Cairo, Egypt 1–3 February 1994 WHO-EM/TUB/184-E/L 2 World Health organization WHO Report 2011 Global Tuberculosis control 2011 World Health Organization 20 Avenue Appia, 1211–Geneva–27, Switzerland 978 92 4 156438 0 3 Peter RD Paul DV The global burden of tuberculosis-combating drug resistance in difficult times N Engl J Med J 2009 360 23 2393 2395 4 World Health Organization Groups at risk: WHO report on tuberculosis epidemic 1996 WHO/TB/96.198 5 Geeta Pardeshi I Survival analysis and risk factors for death in tuberculosis patients on directly observed treatment-short course Indian J Med Sci 5 2009 63 5 180 186 19584488 6 WHO Tuberculosis programme: Framework for effective tuberculosis control World Health Organization 20 Avenue Appia, 1211–Geneva–27, Switzerland 1994 WHO/TB/94/179 7 Mathew TA Ovsyanikova TN Shin SS Gelmanova I Balbuena DA Causes of deaths during tuberculosis treatment in Tomsk Oblast, Russia INt J Tuber Lung Dis 2006 10 8 857 863 8 Lefebvre N Falzon D Risk factors for death among tuberculosis cases: analysis of European surveillance data Eur Respir J 2008 31 6 1256 1260 18515556 9 Oursler KK Moore RD Bishai WR Harrington SM Pope DS Chaisson RE Survival of patients with pulmonary tuberculosis: Clinical and molecular epidemiologic factors Clin Infect Dis 2002 34 6 752 759 11850859 10 Abouzeid MS Zumla AI Felemban S Alotaibi B O’Grady J 2012 Tuberculosis Trends in Saudis and Non-Saudis in the Kingdom of Saudi Arabia – A 10 Year Retrospective Study (2000–2009) PLoS ONE 7 6 e39478 10.1371/journal.pone.0039478 22745765 11 World Health organization Global Tuberculosis Control. WHO report 2011 Global Tuberculosis control 2011 Geneva (WHO/HTM/TB/2011.16) 12 Al-Kahtani NH Al-jeffri MH Manual of the National TB Control Program 2003 (2ndeds, JAD Printing Press) Assistant Deputy for Preventive Medicine, Ministry of Health Kingdom of Saudi Arabia 13 UNITED NATIONS The Millennium Development Goals Report 2011 United Nations New York 11-31339–June 2011–31 978-92-1-101244-6 46 14 World Health Organization Global tuberculosis control: surveillance, planning, financing WHO report 2005 Geneva (WHO/HTM/TB/2005.349) 15 World Health Organization International statistical classification of diseases and related health problems - 10th revision, edition 2010 Geneva 978 92 4 154834 2 16 Ochoa EG Oliva GE Gutiérrez SB González AP Pérez LA Tuberculosis Mortality Trends in Cuba, 1998 to 2007 MEDICC Rev 2009 1 11 1 42 7 21483326 17 Sterling TR Zhao Z Khan A Chaisson RE Schluger N Mangura B A: Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors Int J Tuberc Lung Dis 2006 10 5 542 549 16704037 18 Walpola HC Siskind V Patel AM Konstantinos A Derhy P Tuberculosis-related deaths in Queensland, Australia, 1989–1998: characteristics and risk factors Int J Tuberc Lung Dis 2003 7 8 742 750 12921150 19 Blumberg HM Burman WJ Chaisson RE Daley CL Etkind SC Friedman LN Treatment of tuberculosis Am J Respir Crit Care Med 2003 167 4 603 662 12588714 20 World Health Organization/International Union Against Tuberculosis and Lung Disease Global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the world Report no 2, prevalence and trends WHO/CDS/TB/2000.278 Geneva, Switzerland WHO 2000 21 Balasubramanian R Garg R Santha T Gopi PG Subramani R Chandrasekaran V Gender disparities in tuberculosis: report from a rural DOTS programme in south India Int J Tuberc Lung Dis 2004 8 3 323 332 15139471 22 Kulkarni MS Vaz FS Motghare DD Ferreira AM Trends of tuberculosis mortality rates in Goa 1991–2001 NTI Blletin 2007 43 1&2 9 13 23 Lefebvre N Falzon D Risk factors for death among tuberculosis cases: analysis of European surveillance data Eur Respir J 2008 31 6 1256 1260 18515556 24 Shen X DeRiemer K Yuan Z Shen M Xia Z Gui X Deaths among tuberculosis cases in Shanghai, China: who is at risk? BMC Infectious Diseases 2009 9 95 19531267 25 Davies PDO Darbyshire J Nunn AJ Byfield SP Fox W Citron KM Ambiguities and inaccuracies in the notification system for tuberculosis in England and Wales J Public Health 1981 3 2 108 118 26 Lawn SD Churchyard G Epidemiology of HIV-associated tuberculosis Curr Opin HIV AIDS 2009 4 325 333 19532072 27 MacPherson P Dimairo M Bandason T Zezai A Munyati SS Butterworth AE Risk factors for mortality in smear-negative tuberculosis suspects: a cohort study in Harare, Zimbabwe Int J Tuberc Lung Dis 2011 10 15 10 1390 1396 22283900 28 UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance Epidemiological Fact Sheet on HIV and AIDS, Saudi Arabia, 2008 update Available at: http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_SA.pdf Accessed on 25/8/2010 29 Daiiel OJ Salako AA Ogunfowora OB Oluwole FA Trends in tuberculosis mortality in Nigeria Afr J Clin Exper Microbiol 2007 8 2 137 144